Posted by Michael Wonder on 09 Nov 2019
Teva and Celltrion announce the availability of Truxima (rituximab-abbs) injection, the first biosimilar to Rituxan (rituximab) in the United States
7 November 2019 - Truxima available week of November 11.
Teva Pharmaceuticals and Celltrion today announced that Truxima (rituximab-abbs) injection is the first biosimilar to the reference product Rituxan (rituximab) now available in the United States with a full oncology label.
Truxima is currently indicated for the treatment of adult patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia.
